EMA to review Teva’s MAA for migraine prevention drug fremanezumab
Fremanezumab is an anti-calcitonin gene-related peptide (CGRP) antibody, which is intended to be given as a quarterly or monthly injection. The CGRP ligand is known to be a
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.
It was approved to treat HABP/VABP caused by the following susceptible Gram-negative microorganisms: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae
The new company, named as Theramex, will manufacture products focused on women and their health. Theramex includes Teva’s formerly-owned women’s health product portfolio across contraception, fertility, menopause and
The acquisition would improve Seattle Genetics' late-stage clinical pipeline with Tucatinib, an orally available and highly selective tyrosine kinase inhibitor (TKI) for patients with HER2-positive metastatic breast cancer As per the terms